The company also has a R&D center in India that conducts research in rabies, hepatitis b and measles among others

Clocking an estimated revenue of 283 crore, Indian Immunologicals has shown improvement from 2009-10 revenue of 272.87 crore. With an aim to make immunity affordable to both animal and humans alike, Indian Immunologicals, has grown to be one of the largest biologicals company in
India since its inception in 1983.

In 2010, the company introduced Folyson, a dairy cattle hormone, which indirectly enhances the milk production capacity of a dairy cow or buffalo.

Furthermore, motivated by the success of the foot and mouth disease vaccine, Raksha, the company went on to launch its tissue culture vaccine, Raksharab, and also successfully produced and marketed its human anti-rabies vaccine, called Abhayrab.

With a 213-acre complex in Hyderabad, which has the distinction of being WHO-GMP and ISO-9002 certified,
Indian Immunologicals has one of the world’s largest veterinary vaccine plants in the world, equipped with state-of-the-art technology to manufacture and market vaccines to the masses.

In the animal health sector, Indian Immunologicals manufactures vaccines for foot and mouth diseases, clostridium perfringens, sheep pox, brucella abortus, theileriosis and bacillus anthracis among others. It is also actively engaged in the production of other animal health products.

In the human health sector, Indian Immunologicals has made a significant progress through its cell culture rabies vaccine, Abhayrab. This vaccine is sold by Abhay Clinics, which belong to the marketing network of Indian Immunologicals. The success of this anti-rabies vaccine has influenced the company to venture deeper into this domain by establishing two manufacturing facilities, one in Ooty and another in Hyderabad, India.

The manufacturing facility of the company that is located in Hyderabad is equipped to produce vaccines such as  hepatitis-b, diphtheria, pertussis, tetanus and measles. The company has another R&D center in India that conducts research in rabies, hepatitis b and measles among others.

The company’s marketing network is widespread with over 19 marketing outlets spread across India. In addition to the domestic network, the company also has significant export connections, supplying animal health vaccines to over 20 countries apart from the Food and Agriculture Organization (FAO) of the US. More than 12 countries across the world are receivers of Indian Immunologicals’ human anti-rabies vaccine, Abhayrab. The export market of the company is extremely diversified. It is spread across several countries including, the Gulf, Asia, Africa, Europe, Russia and other CIS nations.

The company has research collaborations with several renowned institutions like Thomas Jefferson Medical School, Onderstepoort Veterinary Institute and Institute of Animal Health among others. Indian Immunologicals aims to combat infectious diseases in animals and human beings by producing affordable products for the betterment of mankind.